Ontology highlight
ABSTRACT:
PROVIDER: PRJNA484054 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR7635274_1.fastq.gz | Fastqsanger.gz | |||
| SRR7635274_2.fastq.gz | Fastqsanger.gz | |||
| SRR7635275_1.fastq.gz | Fastqsanger.gz | |||
| SRR7635275_2.fastq.gz | Fastqsanger.gz | |||
| SRR7635276_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 8 |
Similar Datasets
Project description:Bladder cancer is the fifth most prevalent cancer in the U.S., yet is understudied and relatively lacking in suitable models. Here we describe a biobank of patient-derived organoid lines that recapitulates the spectrum of human bladder cancer at the histopathological and molecular levels. Organoid lines can be established efficiently from patient biopsies, including from patients before and after disease recurrence, and are interconvertible with orthotopic xenografts. Notably, these organoid lines often retain tumor heterogeneity and exhibit changes in their mutational profiles that are consistent with tumor evolution in culture. Analyses of drug response using bladder tumor organoids show partial correlations with mutational profiles as well as changes associated with treatment resistance, and specific responses can be validated using xenografts in vivo. Overall, our studies indicate that patient-derived bladder tumor organoids represent a model system for studying tumor evolution and treatment response in the context of precision cancer medicine.
2018-04-09 | GSE103990 | GEO
Project description:Patient derived organoids (PDOs) closely resemble individual tumor biology. They are thus promising models for drug discovery and precision medicine. Here, we describe high-throughput imaging and automated image analysis of PDOs. We generated PDOs from colorectal cancer patients. Subsequently, we treated them with >500 substances to capture almost 6 million images by confocal microscopy. We developed a software framework to analyze how perturbations alter the organization of multicellular PDOs. Therewith, we observed a rich spectrum of reoccurring phenotypes. Targeting cellular processes, including signaling by MEK, GSK3 or CDKs, led to distinct architectural changes. Also, we detected compound-induced phenotypes only present in subsets of PDOs with specific molecular alterations. Finally, PDO response to anticancer drugs matched the clinical course of corresponding patients. The presented high-throughput imaging workflow and data allow compound profiling with complex multicellular organoid models for drug discovery and personalized medicine. We used microarrays to detail the global programme of gene expression underlying different lines of patient-derived colorectal cancer organoids.
2019-03-03 | GSE117548 | GEO
Project description:Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome caused by germline mutations in TP53. TP53 is the most common mutated gene in human cancer occurring in 30-50% of glioblastomas (GBM). Here, we highlight a precision medicine platform to identify potential targets for a GBM patient with LFS. We used novel comparative transcriptomics analysis to identify genes that are uniquely overexpressed in a LFS GBM patient relative to a cancer compen-dium of 12,747 tumor RNA sequencing datasets including 200 GBMs. We then used ex vivo pa-tient derived organoid (PDO) viability assays with 4 patient derived cell lines to test efficacy of our identified target. Our comparative transcriptomics bioinformatics pipeline identified that STAT1 and STAT2 were significantly overexpressed in our patient indicating ruxolitinib, a Janus kinase 1 and 2 inhibitor, as a potential therapy. In our institutional high-grade glioma cohort of 45 patients, the LFS patient had the highest level of STAT1 and STAT2 expression. STAT1 and STAT2 expression levels in 4 cell lines derived from patients (including the LFS patient) corre-lated with levels identified in the respective parent tumors. Using 2D and 3D assays from pa-tient derived cells, our LFS patient of interest was among the most sensitive to ruxolitinib in comparison to patients with lower STAT1 and STAT2 expression levels. Additionally a sphe-roid-based drug screening assay (3D-PREDICT) was performed and used to identify further therapeutic targets. This manuscript supports the use of comparative transcriptomics to identify personalized therapeutic targets in a functional precision medicine platform for malignant brain tumors.
2021-12-02 | GSE188739 | GEO
Project description:Despite significant advances in cancer diagnosis and treatment, osteosarcoma (OSA), an aggressive primary bone tumor, has eluded attempts at improving patient survival for many decades. The difficulty in managing OSA lies in its extreme genetic complexity, drug-resistance, and heterogeneity, making it improbable that a single-target treatment would be beneficial for the majority of affected individuals. Precision medicine seeks to fill this gap by addressing the intra- and inter-tumoral heterogeneity to improve patient outcome and survival. Characterization of differentially expressed genes (DEGs) unique to the tumor provides insight into the phenotype and can be useful for informing appropriate therapies as well as development of novel treatments. Traditional DEG analysis combines patient data to derive statistically inferred genes that are dysregulated in the group; however, the results from this approach are not necessarily consistent across individual patients, thus contradicting the basis of precision medicine. Spontaneously occurring OSA in the dog shares remarkably similar clinical, histological, and molecular characteristics to the human disease and therefore serves as an excellent model. In this study, we use transcriptomic sequencing of RNA isolated from primary OSA tumor and patient-matched normal bone from seven dogs prior to chemotherapy to identify DEGs in the group. We then evaluate the universality of these changes in transcript levels across patients to identify DEGs at the individual level. These results can be useful for reframing our perspective of transcriptomic analysis from a precision medicine perspective by identifying variations in DEGs among individuals.
2022-04-10 | GSE199489 | GEO
Project description:Multi-dimensional genomic analysis identifies a class of breast cancer patients with high metastatic outcome and differential response to chemotherapeutic drugs The application of multi-dimensional genomic analyses might provide a more refined risk assessment of breast tumor aggressiveness and improve the selection of patients for personalized medicine. Our study demonstrates the feasibility of using CNAs to predict patient outcome. In combination with gene expression profiles, the clinical implication for such prognostic assays is the identification of breast cancer patients at different risks and sensitivities to chemotherapeutic drugs. Keywords: survival time
2009-05-05 | GSE10099 | GEO
Project description:Here we present a functional multi-omics method, interaction-Correlated Multi-omic Aberration Patterning or iC-MAP, which dissects intra-tumor heterogeneity and identifies in situ in real time the oncogenic consequences of multi-omics aberrations that drive proliferative/invasive tumor in individuals with poor prognosis. First, given epigenetic aberrations resulting from complex interactions between genetic susceptibility and environmental influences are the primary driving force of tumorigenesis, we applied our chromatin activity-based chemoproteomics (ChaC) method to characterize the tumor-phenotypic epiproteomes (epigenetic regulatory proteomes) in breast cancer (BC) patient tissues. A biotinylated ChaC probe UNC0965 that specifically binds to the oncogenically active histone methyltransferase G9a enabled the sorting/enrichment of a G9a-interacting epiproteome representing the predominant BC subtype in a tissue, which is separated from other cell types, especially non-malignant cells where G9a is less enzymatically active. ChaC then identified UNC0965-captured G9a interactors that are mostly involved in the oncogenic pathways associated with tumor cell viability and invasion. Using BC patient transcriptomic/genomic data we retrospectively identified the G9a interactor-encoding genes that show individualized iC-MAP in BC-subtypic patients with incurable metastatic disease, revealing essential drivers of proliferative or invasive BC phenotypes. Our iC-MAP findings can not only act as new diagnostic/prognostic markers to identify patient subsets with metastatic disease but also create precision therapeutic strategies that can match proliferative or invasive potential of individual patients.
2019-07-26 | PXD013795 | Pride
Project description:try to find out the genetic sites (genotype) relevant to child bone marrow suppression induced by mercaptopurine. It is a research in pharmacogenomics and precision medicine, which aims to treat each patient individually.
2020-01-19 | E-MTAB-8613 | biostudies-arrayexpress
Project description:We identified XPO1 as an aberrantly activated, non-oncogene encoded targetable vulnerability in pediatric renal tumors (Wilms and malignant rhabdoid tumor [MRT]) using OncoTarget, a Master Regular-based precision cancer medicine tool. We demonstrate significant anti-tumor activity of selinexor and eltanexor, two selective XPO1 inhibitors, in patient derived xenograft mice models of Wilms and MRT, and report on a case of successful treatment of a pediatric cancer patient.
2022-03-09 | GSE198000 | GEO
Project description:The fallopian tubes are essential to several physiological and pathological processes from pregnancy to ovarian cancer. However, current in vitro models to study their pathophysiology were validated using two-dimensional (2D) tissue sections and measuring the organoid response to female hormone stimulation. These analyses overlook the 3D heterogeneity of the tissue and the fallopian tube mechanical function (transport of an oocyte). We developed a multi-compartment organoid model of the human fallopian tube that was meticulously tuned to reflect the compartmentalization and heterogeneity of the tissue composition. We validated the proteome, cilia-driven transport function, and architectural accuracy of this organoid through a novel platform wherein organoids are quantitatively compared to a 3D single-cell resolution reference map of a healthy, transplantation-quality human fallopian tube. This organoid model was precision-engineered using our iterative platform to resemble the cellular and extracellular proteome, biological function, and 3D microanatomy of the human fallopian tube.
2023-08-12 | MSV000092646 | MassIVE
Project description:Tumors show substantial amounts of cellular heterogeneity by forming complex ecosystems of malignant and non-malignant cells. Herein, we present a comprehensive multi-omic cell atlas of matched single-cell transcriptome and single-cell chromatin accessibility profiles spanning over 150,000 cells from 11 human gynecologic tumors. By jointly analyzing these transcriptomic and chromatin accessibility profiles at single-cell resolution, we identify 115,734 total peak-to-gene links representing putative regulatory interactions. We find some of these regulatory interactions explain cell type-specific expression patterns of hallmark cancer pathway regulators such as the mTOR activator RHEB. We also leverage these data to infer differential transcription factor activity, such as ZEB1, across cell type-specific enhancers between two different fractions of the same patient tumor. Our work highlights the importance of precision medicine in the treatment of gynecologic cancers and we show that this resource will deepen our understanding of non-coding genomic regions in the context of tumor biology.
2021-11-04 | GSE173682 | GEO